Skip to main content

Table 1 Enrolled and non-enrolled potentially eligible patients

From: A prospective study investigating gross motor function of children with cerebral palsy and GMFCS level II after long-term Botulinum toxin type A use

Group N

CP Type

N (%)

Last GMFCS

N (%)

Comorbidity = Yes

N (%)

Total number lower limb BoNTA received by an individual

Median (IQR)

Indicationa

N

Age (yrs) first BoNTA

Median (IQR)

Age (yrs) last BoNTA

Median (IQR)

N (%) children undergoing surgery

N by indication

Age (yrs) first surgery

Median (IQR)

Non-enrolled 27

Hemiplegia 9 (34)

Stable 17 (63)

12 (44.4)

7 (5.5, 14.5)

Improve function 15

4 (2, 6)

10 (8, 11)

8 (30) Total

5 Gait only

1 Hips only

2 Hip and Gait

7.5 (4, 11)

Diplegia 16 (59)

Improved 7 (26)

Manage symptoms 3

Quadriplegia 2 (7)

Deteriorated 3 (11)

Care and comfort 2

Enrolled 28

Hemiplegia 13 (46)

Stable 22 (78)

15 (54)

11 (6.71, 5.5)

Improve function 23

3.5 (2, 6)

10 (8.5, 11)

4 (14) Gait only 9 (7, 11)

Diplegia 15 (54)

Improved 6 (22)

Manage symptoms 1

Deteriorated 0 (0)

  1. aThe data fields concerning these indications for use were introduced into the database only in 2013 so data for this field is incomplete